Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 78.2%

Neg 0% Neu 0% Pos 78.2%

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $18 to $22.